180 related articles for article (PubMed ID: 25245280)
21. Preparation of Internalizing RGD-Modified Recombinant Methioninase Exosome Active Targeting Vector and Antitumor Effect Evaluation.
Xin L; Yuan YW; Liu C; Zhou LQ; Liu L; Zhou Q; Li SH
Dig Dis Sci; 2021 Apr; 66(4):1045-1053. PubMed ID: 32323072
[TBL] [Abstract][Full Text] [Related]
22. [Antitumor and antimetastatic effect of antimicrobial peptide conjugated with tumor homing peptide TMTP1 on the transplanted prostate cancer and gastric cancer in nude mice].
Ma XY; Li S; Luo DF; Liu RH; Lu YP; Wang SX; Ma D; Xi L
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):737-41. PubMed ID: 24378093
[TBL] [Abstract][Full Text] [Related]
23. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1.
Lao X; Liu M; Chen J; Zheng H
PLoS One; 2013; 8(8):e72242. PubMed ID: 23977262
[TBL] [Abstract][Full Text] [Related]
24. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
[TBL] [Abstract][Full Text] [Related]
25. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
[TBL] [Abstract][Full Text] [Related]
26. Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy.
Cho HJ; Park SJ; Lee YS; Kim S
J Control Release; 2019 Apr; 300():73-80. PubMed ID: 30831135
[TBL] [Abstract][Full Text] [Related]
27. Application of a proapoptotic peptide to intratumorally spreading cancer therapy.
Chen R; Braun GB; Luo X; Sugahara KN; Teesalu T; Ruoslahti E
Cancer Res; 2013 Feb; 73(4):1352-61. PubMed ID: 23248118
[TBL] [Abstract][Full Text] [Related]
28. Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD.
Fadeev R; Chekanov A; Solovieva M; Bezborodova O; Nemtsova E; Dolgikh N; Fadeeva I; Senotov A; Kobyakova M; Evstratova Y; Yakubovskaya R; Akatov V
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691192
[TBL] [Abstract][Full Text] [Related]
29. Sequential Delivery and Cascade Targeting of Peptide Therapeutics for Triplexed Synergistic Therapy with Real-Time Monitoring Shuttled by Magnetic Gold Nanostars.
Wu R; Min Q; Guo J; Zheng T; Jiang L; Zhu JJ
Anal Chem; 2019 Apr; 91(7):4608-4617. PubMed ID: 30821439
[TBL] [Abstract][Full Text] [Related]
30. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate.
Peng ZH; Kopeček J
Bioorg Med Chem Lett; 2014 Apr; 24(8):1928-33. PubMed ID: 24656564
[TBL] [Abstract][Full Text] [Related]
32. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.
Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
[TBL] [Abstract][Full Text] [Related]
34. Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability.
Hu C; Chen X; Huang Y; Chen Y
Sci Rep; 2018 Feb; 8(1):2274. PubMed ID: 29396568
[TBL] [Abstract][Full Text] [Related]
35. Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
Kandela I; Chou J; Chow K; ;
Elife; 2015 May; 4():. PubMed ID: 25998055
[TBL] [Abstract][Full Text] [Related]
36. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
37. iRGD-mediated core-shell nanoparticles loading carmustine and O
Liu C; Yao S; Li X; Wang F; Jiang Y
J Drug Target; 2017 Mar; 25(3):235-246. PubMed ID: 27646474
[TBL] [Abstract][Full Text] [Related]
38. Cancer therapy with iRGD as a tumor-penetrating peptide.
Thirumalai A; Girigoswami K; Pallavi P; Harini K; Gowtham P; Girigoswami A
Bull Cancer; 2023 Dec; 110(12):1288-1300. PubMed ID: 37813754
[TBL] [Abstract][Full Text] [Related]
39. Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
Schmithals C; Köberle V; Korkusuz H; Pleli T; Kakoschky B; Augusto EA; Ibrahim AA; Arencibia JM; Vafaizadeh V; Groner B; Korf HW; Kronenberger B; Zeuzem S; Vogl TJ; Waidmann O; Piiper A
Cancer Res; 2015 Aug; 75(15):3147-54. PubMed ID: 26239478
[TBL] [Abstract][Full Text] [Related]
40. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
